Search Medical Condition
Please enter condition
Please choose location from dropdown

Iquitos, Peru Clinical Trials

A listing of Iquitos, Peru clinical trials actively recruiting patients volunteers.

RESULTS

Found (4) clinical trials

Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women Who Have Sex With Men

The purpose of this study is to evaluate the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW). This study will enroll HIV-uninfected MSM and TGW at risk for acquiring ...

Phase

0.68 miles

Learn More »

Demonstration Project on the Feasibility to Implement PrEP in MSM and TG Women

HYPOTHESIS Hypothesis 1. The use of PrEP based on daily intake of TDF/FTC is acceptable for MSM and transgender women and their acceptance correlates with knowledge of PrEP and sexual risk behavior. Hypothesis 2. Adherence and duration of use of PrEP based on daily intake of TDF/FTC correlates with the ...

Phase N/A

1.05 miles

Learn More »

VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents

This is a multicenter,randomized study to evaluate safety, immunogenicity, and efficacy of a 3-dose vaccination regimen with the Zika virus wildtype (ZIKVwt) DNA vaccine, VRC-ZKADNA090-00-VP or placebo (VRC-PBSPLA043-00-VP). The placebo is a sterile phosphate-buffered saline (PBS). The hypotheses are that the ZIKVwt DNA vaccine will be safe and will elicit ...

Phase

1.05 miles

Learn More »

Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men

This study will evaluate the safety, tolerability, and efficacy of the VRC01 antibody in preventing HIV-1 infection in men and transgender (TG) persons who have sex with men, in North America, South America, and Switzerland. Participants will be randomized to receive VRC01 mAb by intravenous (IV) infusion at a dose ...

Phase

1.32 miles

Learn More »